MREO Mereo Biopharma Group Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MREO

Price (delayed)

$0.3403

Market cap

$54.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$25.25M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 11
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10
Highlights
The EPS has grown by 43% YoY and by 20% from the previous quarter
The net income has increased by 43% year-on-year and by 21% since the previous quarter
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
Mereo Biopharma Group's revenue has shrunk by 100% QoQ and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.mereobiopharma.com
Peers: NTLA ALLO CRSP EDIT

Key stats

What are the main financial stats of MREO

MREO stock price

How has the Mereo Biopharma Group stock price performed over time
Intraday
7.59%
1 week
27.93%
1 month
17.18%
1 year
-81.09%
YTD
-18.33%
QTD
7.11%

Financial performance

How have Mereo Biopharma Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$34.5M
Net income
-$28.1M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
Mereo Biopharma Group's revenue has shrunk by 100% QoQ and by 100% YoY
The net income has increased by 43% year-on-year and by 21% since the previous quarter
The operating income has grown by 26% YoY and by 9% from the previous quarter

Price vs fundamentals

How does MREO's price correlate with its fundamentals

Growth

What is Mereo Biopharma Group's growth rate over time

Valuation

What is Mereo Biopharma Group stock price valuation
P/E
N/A
P/B
1.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY and by 20% from the previous quarter
The equity has declined by 47% year-on-year and by 16% since the previous quarter
The P/B is 41% lower than the last 4 quarters average of 3.0
Mereo Biopharma Group's revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Mereo Biopharma Group business performance
MREO's ROA is up by 9% QoQ and by 3.9% YoY
The return on equity has grown by 8% since the previous quarter and by 7% year-on-year

Dividends

What is MREO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MREO.

Financial health

How did Mereo Biopharma Group financials performed over time
MREO's total assets is down by 45% year-on-year and by 15% since the previous quarter
The quick ratio has contracted by 29% YoY and by 9% from the previous quarter
Mereo Biopharma Group's debt is 96% lower than its equity
Mereo Biopharma Group's debt has surged by 71% YoY
The equity has declined by 47% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.